<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael D Jibson, MD, PhD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Stephen Marder, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Michael Friedman, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 09, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H272233773">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antipsychotic medications have been used since the 1950s to treat psychosis; they can be used to treat acute psychosis from any cause and to manage chronic psychotic disorders such as schizophrenia. As a class, antipsychotics are also effective in the treatment of acute agitation, bipolar mania, and other psychiatric conditions.
        </p>
        <p>
         First-generation antipsychotics (FGAs), also known as neuroleptics, conventional or typical antipsychotics, have significant potential to cause extrapyramidal symptoms and tardive dyskinesia. This propensity to cause movement disorders is the primary difference between FGAs and second-generation antipsychotics (SGAs). In other respects, such as other side effects and their mechanism of action, the two classes have substantial overlap and comparable efficacy.
        </p>
        <p>
         The pharmacology,
         <strong>
         </strong>
         administration, and side effects of FGAs are discussed here. The pharmacology,
         <strong>
         </strong>
         administration, and side effects of SGAs are discussed separately. The efficacy and administration of antipsychotic drugs for specific psychotic disorders are also described separately, as are antipsychotic poisoning, tardive dyskinesia, neuroleptic malignant syndrome, and other antipsychotic drug side effects.
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14776.html" rel="external">
          "Second-generation antipsychotic medications: Pharmacology, administration, and side effects"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">
          "Schizophrenia in adults: Maintenance therapy and side effect management"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/679.html" rel="external">
          "Bipolar mania and hypomania in adults: Choosing pharmacotherapy"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14686.html" rel="external">
          "Unipolar major depression with psychotic features: Epidemiology, clinical features, assessment, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14780.html" rel="external">
          "Delusional disorder"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/14778.html" rel="external">
          "Brief psychotic disorder"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/6964.html" rel="external">
          "Treatment of postpartum psychosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/315.html" rel="external">
          "First-generation (typical) antipsychotic medication poisoning"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/304.html" rel="external">
          "Second-generation (atypical) antipsychotic medication poisoning"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4909.html" rel="external">
          "Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">
          "Neuroleptic malignant syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H272233780">
         <span class="h1">
          PHARMACOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The mechanism of action of all first-generation antipsychotics (FGAs) appears to be postsynaptic blockade of brain dopamine D2 receptors. Evidence supporting this mechanism includes strong antagonism of D2 receptors in both cortical and striatal areas [
         <a href="#rid1">
          1
         </a>
         ], a high correlation between D2 receptor binding and clinical potency [
         <a href="#rid2">
          2
         </a>
         ], and a consistent requirement of 65 percent D2 receptor occupancy for antipsychotic efficacy in functional imaging studies [
         <a href="#rid3">
          3
         </a>
         ]. The nonspecific localization of FGA dopamine binding throughout the central nervous system is consistent with their risk of movement disorders and prolactinemia. Aside from their common activity as D2 antagonists, each FGA has distinct effects on neuronal 5-HT2a, alpha-1, histaminic, and muscarinic receptors, which generally correspond to their individual side effect profiles, as shown in the table  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H16917418">
         <span class="h2">
          High- and low-potency FGAs
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pharmacologic differences described above are the basis for the classification of FGAs as either high- or low-potency drugs:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The high-potency FGAs (
         <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">
          fluphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9576" href="/z/d/drug information/9576.html" rel="external">
          loxapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9773" href="/z/d/drug information/9773.html" rel="external">
          pimozide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9993" href="/z/d/drug information/9993.html" rel="external">
          thiothixene
         </a>
         , and
         <a class="drug drug_general" data-topicid="10020" href="/z/d/drug information/10020.html" rel="external">
          trifluoperazine
         </a>
         ) are dosed in the range of 1 to 10s of milligrams and have low activity at histaminic and muscarinic receptors. They are associated with little sedation, weight gain, or anticholinergic activity, but a high risk for extrapyramidal symptoms (EPS).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The low-potency FGAs (
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         and
         <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">
          thioridazine
         </a>
         ) are dosed in 100s of milligrams and have high histaminic and muscarinic activity with a corresponding increased prevalence of sedation and anticholinergic effects, but lower risk of EPS. Chlorpromazine and thioridazine have significantly greater adverse effects (eg, blurred vision, ocular toxicity, orthostatic hypotension, QTc prolongation, and urinary retention) relative to other antipsychotics; generally, many better tolerated options are preferred to these low-potency FGAs. (See
         <a class="local">
          'Side effects'
         </a>
         below.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16917445">
         <span class="h2">
          Absorption and bioavailability
         </span>
         <span class="headingEndMark">
          —
         </span>
         Oral absorption of the FGAs may be erratic and several of the drugs undergo extensive first-pass metabolism by the liver, yielding low or variable oral bioavailability. FGAs are lipophilic, highly protein- and tissue-bound as a class with large volumes of distribution. Each of these factors varies substantially among patients, making it difficult to predict serum drug levels based on dose alone. Meaningful guidelines for therapeutic drug levels have been similarly elusive, even for
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         , the most widely studied of these drugs [
         <a href="#rid4">
          4,5
         </a>
         ]. Each of these factors should be considered as the clinician assesses the patient’s clinical response to an initial dose of the medication.
        </p>
        <p>
         The most readily absorbed FGAs are
         <a class="drug drug_general" data-topicid="9576" href="/z/d/drug information/9576.html" rel="external">
          loxapine
         </a>
         and
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         , with times to peak serum concentration of one to three hours. Other drugs are less predictably absorbed. An oral dose of
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         , for example, may require anywhere from two to six hours to reach peak concentration. The intramuscular formulation of loxapine requires five hours to be fully absorbed, more than twice as long as its oral counterpart. Loxapine has the highest bioavailability among these drugs at nearly 100 percent, in contrast to haloperidol at 60 percent and
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         ’s 20 percent. Predictable changes in bioavailability with food have not been reported with any of the drugs.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9576" href="/z/d/drug information/9576.html" rel="external">
          Loxapine
         </a>
         has a unique aerosol formulation that reaches peak plasma concentration within two minutes following use, with little variation among subjects [
         <a href="#rid6">
          6
         </a>
         ]. The clinical effect of the drug on psychotic agitation in schizophrenia and bipolar mania patients was reported within 10 minutes of administration [
         <a href="#rid7">
          7,8
         </a>
         ]. (See
         <a class="local">
          'Administration'
         </a>
         below.)
        </p>
        <p class="headingAnchor" id="H16917564">
         <span class="h1">
          METABOLIC ACTIVATION AND CLEARANCE
         </span>
         <span class="headingEndMark">
          —
         </span>
         All FGAs are subject to extensive metabolism via the cytochrome P450 system, and several use an additional glucuronidation pathway. This dependence on hepatic clearance makes the drugs susceptible to liver impairment and drug-drug interactions. (See
         <a class="local">
          'Drug-drug interactions'
         </a>
         below.)
        </p>
        <p>
         The CYP-2D6 gene is polymorphic and increased serum concentrations of
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         and
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         , as well as more prominent side effects, such as over-sedation, have been described among CYP-2D6 slow metabolizers [
         <a href="#rid9">
          9,10
         </a>
         ]. In the case of
         <a class="drug drug_general" data-topicid="9773" href="/z/d/drug information/9773.html" rel="external">
          pimozide
         </a>
         , the maximum daily dose should be reduced from 10 mg to 4 mg in slow metabolizers. No specific dose adjustments in slow or extensive metabolizers are recommended for other FGAs. Specific metabolic pathways used by individual drugs are listed in the table  (
         <a class="graphic graphic_table graphicRef60624" href="/z/d/graphic/60624.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p>
         Most FGAs have clearance half-times of 20 to 40 hours, and several have active metabolites, factors that lead to relatively stable serum levels with once daily administration. Recommendations for more frequent dosing are usually based on side effect management rather than pharmacokinetics. The presence of active metabolites may complicate predictions of how long it will take a drug to be cleared, as in the case of
         <a class="drug drug_general" data-topicid="9576" href="/z/d/drug information/9576.html" rel="external">
          loxapine
         </a>
         , which has two active metabolites that give it more complex pharmacokinetics than other antipsychotics [
         <a href="#rid11">
          11
         </a>
         ]. This is favorable in the case of
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         ’s active metabolite, 7-hydroxyperphenazine, whose 19-hour clearance time gives the medication a longer duration of activity than the relative short clearance half-time of the parent compound would suggest. A possible negative effect has been suggested for
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ’s metabolite pyridinium, which has been cited as potentially neurotoxic [
         <a href="#rid12">
          12
         </a>
         ]. Pharmacokinetics of the FGAs are described in the table  (
         <a class="graphic graphic_table graphicRef60624" href="/z/d/graphic/60624.html" rel="external">
          table 2
         </a>
         ).
        </p>
        <p class="headingAnchor" id="H16917708">
         <span class="h2">
          Drug-drug interactions
         </span>
         <span class="headingEndMark">
          —
         </span>
         The FGAs can interact with drugs that have potent effects on CYP metabolism, including the antidepressants
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         , which inhibit CYP-2D6, and the mood stabilizer
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         , which induces CYP-1A2 and -3A4  (
         <a class="graphic graphic_table graphicRef60624" href="/z/d/graphic/60624.html" rel="external">
          table 2
         </a>
         ). The impact of CYP induction or inhibition on serum levels of most FGAs is moderated somewhat in the drugs that have multiple pathways for clearance, including
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9576" href="/z/d/drug information/9576.html" rel="external">
          loxapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">
          thioridazine
         </a>
         .
        </p>
        <p>
         <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">
          Fluphenazine
         </a>
         has a single primary pathway via CYP-2D6 and is more susceptible to interactions with inhibitors of this enzyme than are other FGAs. Fluphenazine is not recommended for concurrent use with strong CYP-2D6 inhibitors.
         <a class="drug drug_general" data-topicid="9773" href="/z/d/drug information/9773.html" rel="external">
          Pimozide
         </a>
         levels are moderately sensitive to inhibition of CYP-2D6, but due to the risk for QTc-interval prolongation, the use of pimozide with strong CYP2D6 inhibitors is contraindicated.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          Chlorpromazine
         </a>
         is also sensitive to induction of CYP-1A2, such as occurs with heavy smoking, a quality it shares with
         <a class="drug drug_general" data-topicid="9993" href="/z/d/drug information/9993.html" rel="external">
          thiothixene
         </a>
         . A patient who is stabilized on one of these drugs in a nonsmoking environment, such as a hospital, may experience a drop in serum levels upon returning home and resuming smoking. In each of these cases, a moderate dose increase may be required [
         <a href="#rid13">
          13-15
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16917799">
         <span class="h1">
          ADMINISTRATION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Due to the propensity of first-generation antipsychotics (FGAs) to cause extrapyramidal symptoms and tardive dyskinesia, second-generation antipsychotics are typically the preferred choice over FGAs in the treatment of psychosis. This is discussed in detail elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">
          "Schizophrenia in adults: Maintenance therapy and side effect management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/130944.html" rel="external">
          "Psychosis in adults: Initial management", section on 'Selection'
         </a>
         .)
        </p>
        <p>
         When used, oral dosing of FGAs is the preferred route of administration in most patients. A table describes the usual oral starting dose, dose range and maximum dose, and formulations  (
         <a class="graphic graphic_table graphicRef60624" href="/z/d/graphic/60624.html" rel="external">
          table 2
         </a>
         ). Once-daily dosing is indicated for most of the FGAs. More frequent administration may be useful in some cases to minimize side effects. Dosing at bedtime is generally preferred because of the sedation associated with the drugs, but exceptions for individual patients are common and the medications work equally well irrespective of the time of the dose.
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9576" href="/z/d/drug information/9576.html" rel="external">
          Loxapine
         </a>
         is available for administration as a heat-generated aerosol of particles appropriate for deep lung delivery [
         <a href="#rid6">
          6
         </a>
         ]. The drug is given as a single inhaled dose that is absorbed rapidly and completely. This formulation is approved for once-daily dosing for control of psychotic agitation. (See
         <a class="local">
          'Absorption and bioavailability'
         </a>
         above.)
        </p>
        <p>
         Intramuscular injectable formulations of antipsychotic drugs for acute indications  (
         <a class="graphic graphic_table graphicRef60846" href="/z/d/graphic/60846.html" rel="external">
          table 3
         </a>
         ) and long-acting injectable formulations  (
         <a class="graphic graphic_table graphicRef59201" href="/z/d/graphic/59201.html" rel="external">
          table 4
         </a>
         ) are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/291.html" rel="external">
          "Assessment and emergency management of the acutely agitated or violent adult"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/15250.html" rel="external">
          "Schizophrenia in adults: Pharmacotherapy with long-acting injectable antipsychotic medication"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H272233794">
         <span class="h1">
          SIDE EFFECTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         While all antipsychotic medications are believed to be comparable in effectiveness (with the exception of
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         for treatment-resistant schizophrenia), they differ in side effect profiles, both individually and between first-generation (FGA) and second-generation (SGA) antipsychotics. The choice of an antipsychotic is often influenced by its side effect profile and its match with the patient’s clinical status and vulnerabilities. As examples:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A sedating antipsychotic, such as
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         , might be used for a patient with psychosis and insomnia.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An antipsychotic associated with a lower risk of metabolic syndrome, such as
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         , might be selected in a patient with diabetes, hyperlipidemia, or obesity.
        </p>
        <p>
        </p>
        <p>
         Common side effects associated with FGAs include extrapyramidal symptoms (EPS), tardive dyskinesia, hyperprolactinemia, neuroleptic malignant syndrome, QT prolongation, sudden death, and an increased risk of mortality when used to treat psychiatric symptoms associated with dementia in older adult patients. A table shows the relative likelihood of many of these side effects for individual FGAs  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 1
         </a>
         ). Management of these side effects is described separately. (See
         <a class="medical medical_review" href="/z/d/html/4909.html" rel="external">
          "Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6626.html" rel="external">
          "Causes of hyperprolactinemia"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">
          "Neuroleptic malignant syndrome"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/116011.html" rel="external">
          "Acquired long QT syndrome: Clinical manifestations, diagnosis, and management"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">
          "Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Side effect management'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16917867">
         <span class="h2">
          Extrapyramidal symptoms
         </span>
         <span class="headingEndMark">
          —
         </span>
         The defining difference between FGAs and the newer SGAs is their higher incidence of the akathisia, rigidity, bradykinesia, tremor, and acute dystonic reactions that constitute EPS. As dopamine D2 antagonists, these drugs have the potential to interfere with dopamine transmission via the nigrostriatal tract, which is involved in control of muscle movement, thereby producing symptoms similar to those seen in Parkinson's disease. (See
         <a class="local">
          'Pharmacology'
         </a>
         above.)
        </p>
        <p>
         Among the FGAs, the high-potency drugs
         <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">
          fluphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9576" href="/z/d/drug information/9576.html" rel="external">
          loxapine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9773" href="/z/d/drug information/9773.html" rel="external">
          pimozide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9993" href="/z/d/drug information/9993.html" rel="external">
          thiothixene
         </a>
         are usually associated with the highest risk of EPS. A systematic review found that 21 to 31 percent of patients treated with haloperidol for three to eight weeks experienced drug-induced EPS [
         <a href="#rid16">
          16
         </a>
         ]. The low-potency medications
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         and
         <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">
          thioridazine
         </a>
         are less likely to cause EPS than are the high-potency drugs and in some studies show risk comparable to moderate or high doses of the SGA
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         [
         <a href="#rid17">
          17
         </a>
         ]. A review of schizophrenia treatments in the community found
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         to be associated with a lower rate of EPS than the high-potency FGA haloperidol and comparable to risperidone [
         <a href="#rid18">
          18
         </a>
         ]  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Patients on FGAs should be asked about restlessness, slow movements, shaking, and rigidity at baseline and weekly during dose increases. The Barnes Akathisia Scale or Simpson Angus Scale  (
         <a class="graphic graphic_table graphicRef105378" href="/z/d/graphic/105378.html" rel="external">
          table 5
         </a>
         ) can be useful in documenting akathisia and parkinsonism. (See
         <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">
          "Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Extrapyramidal symptoms'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16917968">
         <span class="h2">
          Tardive dyskinesia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Tardive dyskinesia (TD) is reviewed here briefly; the etiology, epidemiology, assessment, treatment, and prevention of tardive dyskinesia are discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/4909.html" rel="external">
          "Tardive dyskinesia: Etiology, risk factors, clinical features, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/4908.html" rel="external">
          "Tardive dyskinesia: Prevention, treatment, and prognosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">
          "Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Tardive dyskinesia'
         </a>
         .)
        </p>
        <p>
         TD is characterized by involuntary choreoathetoid movements of the mouth, tongue, face, extremities, or trunk, including lip-smacking, tongue writhing or thrusting, jaw movements, facial grimacing, and trunk or extremity writhing. TD risk increases with age, time of exposure to the medications, and prior development of EPS. Although the symptoms are often mild and of limited concern to the patient, they are sometimes progressive and may become disfiguring or disabling.
        </p>
        <p>
         TD has been reported with all FGAs at a cumulative rate of 5 percent per year, with higher risk in the older population [
         <a href="#rid19">
          19-21
         </a>
         ]. The FGAs are considerably more likely to cause TD at all ages than are SGAs, a major reason that the newer drugs have largely supplanted them for maintenance use [
         <a href="#rid22">
          22
         </a>
         ]. It is not clear if there are differences in risk among the FGAs, although the low-potency drugs
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         and
         <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">
          thioridazine
         </a>
         are generally thought to carry less risk based on their lower incidence of EPS. Higher risk has been attributed to
         <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">
          fluphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9773" href="/z/d/drug information/9773.html" rel="external">
          pimozide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9993" href="/z/d/drug information/9993.html" rel="external">
          thiothixene
         </a>
         , and
         <a class="drug drug_general" data-topicid="10020" href="/z/d/drug information/10020.html" rel="external">
          trifluoperazine
         </a>
         (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 1
         </a>
         ).
        </p>
        <p>
         Patients on these medications should be formally assessed for TD every three to six months throughout their course of treatment; high-risk patients, such as those with prominent EPS or older adults, should be assessed at the shorter interval. Standardized assessments, such as the Abnormal Involuntary Movement Scale (AIMS)  (
         <a class="graphic graphic_form graphicRef51103" href="/z/d/graphic/51103.html" rel="external">
          form 1
         </a>
         ) are especially helpful in tracking development and progression of symptoms.
        </p>
        <p class="headingAnchor" id="H16918037">
         <span class="h2">
          Metabolic syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Weight gain, diabetes, dyslipidemia, diabetic ketoacidosis, and cardiovascular disease constitute a metabolic syndrome usually associated with SGAs, but presenting with comparable frequency in FGAs [
         <a href="#rid23">
          23
         </a>
         ]. The mechanism by which these symptoms are produced is not entirely clear, but there is evidence for both increased appetite and altered metabolic control with these drugs [
         <a href="#rid24">
          24
         </a>
         ]. Patient-related factors include preexisting metabolic issues, and those who are obese, diabetic or prediabetic, or have high-risk lipid profiles are more likely to experience problems with these medications than other patients. There is evidence of increased susceptibility in patients with some of the disorders they treat, particularly schizophrenia [
         <a href="#rid25">
          25
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/14805.html" rel="external">
          "Schizophrenia in adults: Maintenance therapy and side effect management", section on 'Metabolic dysregulation'
         </a>
         .)
        </p>
        <p>
         Although no FGA is entirely free of weight gain and related metabolic effects,
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         appears to carry relatively high risk [
         <a href="#rid26">
          26-29
         </a>
         ], whereas
         <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">
          fluphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         , and
         <a class="drug drug_general" data-topicid="9773" href="/z/d/drug information/9773.html" rel="external">
          pimozide
         </a>
         show the lowest risk  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid12">
          12,30-32
         </a>
         ], followed by
         <a class="drug drug_general" data-topicid="9576" href="/z/d/drug information/9576.html" rel="external">
          loxapine
         </a>
         [
         <a href="#rid33">
          33
         </a>
         ]. The potential morbidity of these symptoms has led to recommendations for routine monitoring of weight, waist circumference, blood pressure, fasting glucose, and lipid profile of patients taking any of the antipsychotic drugs  (
         <a class="graphic graphic_table graphicRef74435" href="/z/d/graphic/74435.html" rel="external">
          table 6
         </a>
         ) [
         <a href="#rid34">
          34
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H16918246">
         <span class="h2">
          Anticholinergic effects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antimuscarinic activity is prominent with the low-potency FGAs
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         and
         <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">
          thioridazine
         </a>
         , and commonly results in dry mouth or constipation and less often in blurred vision or urinary retention. These symptoms tend to be mild or absent with the higher-potency drugs. Although no specific monitoring is recommended, patient complaints should be addressed with dose adjustment, medication change, or appropriate medical intervention.
        </p>
        <p class="headingAnchor" id="H16918253">
         <span class="h2">
          Cardiovascular events
         </span>
        </p>
        <p class="headingAnchor" id="H16918260">
         <span class="h3">
          QT interval prolongation and sudden death
         </span>
         <span class="headingEndMark">
          —
         </span>
         Sudden death, believed in most cases to be caused by QT prolongation, has been reported in 1.5 to 1.8 persons per 1000 years of exposure to any antipsychotic drug, more than twice the rate of age-matched controls [
         <a href="#rid35">
          35
         </a>
         ]. Among the first-generation antipsychotics (FGAs),
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">
          thioridazine
         </a>
         , and intravenous
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         are known to be more likely to prolong the QT interval, with
         <a class="drug drug_general" data-topicid="9773" href="/z/d/drug information/9773.html" rel="external">
          pimozide
         </a>
         posing an intermediate level of risk. The amount of prolongation is greatest with thioridazine and pimozide. Several reports, including a 2015 meta-analysis of observational studies found that thioridazine had the highest relative risk among both FGAs and second-generation antipsychotics (SGAs) at more than fourfold the rate of case controls [
         <a href="#rid36">
          36-39
         </a>
         ]. Mesoridazine, an FGA with comparable risk for QT prolongation (and an active metabolite of thioridazine) [
         <a href="#rid40">
          40
         </a>
         ], was discontinued by the manufacturer in 2004 because of this side effect and is no longer available.
        </p>
        <p>
         The US Food and Drug Administration (FDA) and expert guidelines have recommended that
         <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">
          thioridazine
         </a>
         should not be used as a first-line treatment for psychosis. Prior to prescribing thioridazine,
         <a class="drug drug_general" data-topicid="9773" href="/z/d/drug information/9773.html" rel="external">
          pimozide
         </a>
         , or intravenous
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         , patients should receive an electrocardiogram (ECG) and serum potassium level. An ECG should be checked at least annually in patients taking the drugs, including during dose adjustments and in response to any changes in the patient’s cardiac condition. These medications should not be started in a patient with a baseline corrected QT interval (QTc) greater than 450 ms. During treatment, a QTc greater than 500 ms or an increase in QTc of 60 ms or more indicates significant risk for torsade de pointe and merits a change in treatment, such as a dose reduction or switch to a lower-risk antipsychotic [
         <a href="#rid41">
          41,42
         </a>
         ]. Inhibitors of CYP-2D6, such as
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         and
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         , should be avoided with thioridazine, as should drugs that prolong QT interval. (See
         <a class="medical medical_review" href="/z/d/html/116011.html" rel="external">
          "Acquired long QT syndrome: Clinical manifestations, diagnosis, and management"
         </a>
         .)
        </p>
        <p>
         Although oral and intramuscular dosing of
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         have been associated with minimal change in QT interval, intravenous (IV) haloperidol has an elevated risk of prolonged QTc interval and torsades de pointes, especially at doses above 35 mg/day [
         <a href="#rid43">
          43-45
         </a>
         ]. In addition to the initial tests and cautions described above, continuous cardiac monitoring is recommended during acute IV drug administration and for two to three hours thereafter [
         <a href="#rid44">
          44-46
         </a>
         ]. Similar caution should be exercised with IV
         <a class="drug drug_general" data-topicid="9395" href="/z/d/drug information/9395.html" rel="external">
          droperidol
         </a>
         in patients who are medically ill, older adults, or receiving other agents that prolong QT interval [
         <a href="#rid44">
          44,47
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/1616.html" rel="external">
          "Sedative-analgesia in ventilated adults: Medication properties, dose regimens, and adverse effects", section on 'Antipsychotics'
         </a>
         .)
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9773" href="/z/d/drug information/9773.html" rel="external">
          Pimozide
         </a>
         prolongs the QT interval less severely [
         <a href="#rid48">
          48
         </a>
         ], but has been associated with cardiac death in the presence of metabolic inhibitors of CYP-3A4, specifically
         <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">
          clarithromycin
         </a>
         , and in theory, other macrolide antibiotics, antifungals such as
         <a class="drug drug_general" data-topicid="8589" href="/z/d/drug information/8589.html" rel="external">
          ketoconazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="10043" href="/z/d/drug information/10043.html" rel="external">
          verapamil
         </a>
         [
         <a href="#rid49">
          49
         </a>
         ]. For this reason, similar cautions are recommended [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
         <a class="drug drug_general" data-topicid="9576" href="/z/d/drug information/9576.html" rel="external">
          Loxapine
         </a>
         and
         <a class="drug drug_general" data-topicid="9993" href="/z/d/drug information/9993.html" rel="external">
          thiothixene
         </a>
         show only slight changes in QT interval at standard doses, including with the aerosol formulation of loxapine [
         <a href="#rid51">
          51
         </a>
         ]. No data on QT changes are available for
         <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">
          fluphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         , or
         <a class="drug drug_general" data-topicid="10020" href="/z/d/drug information/10020.html" rel="external">
          trifluoperazine
         </a>
         . No special cautions or monitoring are recommended for these drugs. Cardiac monitoring including ECG and potassium levels prior to starting one of these drugs is recommended only for patients with a history of cardiac disease.
        </p>
        <p class="headingAnchor" id="H16918650">
         <span class="h3">
          Orthostatic hypotension
         </span>
         <span class="headingEndMark">
          —
         </span>
         Orthostatic hypotension is most common with
         <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">
          thioridazine
         </a>
         and
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         among FGAs [
         <a href="#rid52">
          52
         </a>
         ], occurring in clinical trials more often than with
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         [
         <a href="#rid28">
          28
         </a>
         ] or
         <a class="drug drug_general" data-topicid="9576" href="/z/d/drug information/9576.html" rel="external">
          loxapine
         </a>
         [
         <a href="#rid53">
          53
         </a>
         ]. Hypotension with chlorpromazine is particularly common when the drug is given parenterally. In contrast, changes in blood pressure are rarely reported with
         <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">
          fluphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         , or
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         . The most likely mechanism of orthostatic hypotension with FGAs is alpha-adrenergic blockade. The condition is often accompanied by orthostatic tachycardia, both of which are most common in the first few days of exposure to the medications or when the dose is being increased. No specific monitoring has been recommended by manufacturers, but lower doses and slower titration may be appropriate for patients with signs of orthostatic changes.
        </p>
        <p class="headingAnchor" id="H16918657">
         <span class="h3">
          Increased risk of mortality
         </span>
         <span class="headingEndMark">
          —
         </span>
         Accumulating data from both observational studies and pooled analyses of randomized trials indicate that antipsychotic medications are associated with an increased risk of stroke, myocardial infarction, and death when used to treat behavioral symptoms in older adults with dementia [
         <a href="#rid54">
          54-58
         </a>
         ]. The mechanism for this effect has not been firmly established. All antipsychotics prescribed in the United States carry a boxed warning from the FDA of a 1.6- to 1.7-fold increase in mortality from all causes for older adult patients with dementia-related psychosis [
         <a href="#rid59">
          59
         </a>
         ].
        </p>
        <p>
         Studies comparing the relative risk of various antipsychotics indicate that FGAs cause somewhat higher mortality than the SGAs [
         <a href="#rid60">
          60-62
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2018 study of 6578 patients hospitalized following a myocardial infarction, which found an adjusted hazard ratio of 1.50 (95% CI 1.14-1.96) for a greater likelihood of death among patients receiving oral
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         compared with those given an SGA (7.8 versus 5.5 percent mortality rate in the seven days following admission) [
         <a href="#rid63">
          63
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A 2017 comparison of mortality rates in a cohort of 70,718 community-based patients with recently diagnosed Alzheimer disease in Finland similarly found a higher adjusted hazard ratio of 1.52 (95% CI 1.14-2.02) for
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         than for
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         (adjusted hazard ratio 0.84, 95% CI 0.75-0.94) [
         <a href="#rid64">
          64
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         No specific monitoring has been suggested to address mortality risk in general, but attention to cardiac and metabolic issues may be helpful, and alternatives to antipsychotic drugs should be used when possible, particularly for behavioral symptoms that are not severe and/or refractory. (See
         <a class="medical medical_review" href="/z/d/html/5082.html" rel="external">
          "Management of neuropsychiatric symptoms of dementia", section on 'Antipsychotic drugs'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H16918732">
         <span class="h2">
          Agranulocytosis
         </span>
         <span class="headingEndMark">
          —
         </span>
         Rare but potentially fatal cases of agranulocytosis, neutropenia, and leukopenia have been reported with all FGAs. There is some evidence that drugs of the phenothiazine class (especially
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         , and to a lesser extent
         <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">
          fluphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">
          thioridazine
         </a>
         , and
         <a class="drug drug_general" data-topicid="10020" href="/z/d/drug information/10020.html" rel="external">
          trifluoperazine
         </a>
         ) carry higher risk than other FGAs. The overall risk of agranulocytosis with these medications is 1 in 10,000 patients, whereas the risk for chlorpromazine is 0.13 percent [
         <a href="#rid65">
          65
         </a>
         ]. For patients taking any FGA who either have previously experienced a drug-induced leukocytopenia or have a preexisting low white blood cell or absolute neutrophil count, monitoring is recommended during the first few months of treatment. A reasonable approach would be a white blood cell and absolute neutrophil count at baseline, after one to two weeks, and after three to six months.
        </p>
        <p class="headingAnchor" id="H16918753">
         <span class="h2">
          Cholestatic jaundice
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          Chlorpromazine
         </a>
         is associated with cholestatic jaundice in 1 to 2 percent of patients [
         <a href="#rid66">
          66
         </a>
         ], usually occurring in the first month of treatment. A proposed mechanism for this effect is an inability of some patients to metabolize chlorpromazine via its usual primary pathway of sulfoxidation, allowing the formation of toxic metabolites via a secondary pathway involving hydroxylation [
         <a href="#rid67">
          67
         </a>
         ]. Rare cases of jaundice have been reported with other FGAs and each carries a manufacturer’s recommendation for annual liver function tests.
        </p>
        <p class="headingAnchor" id="H16918788">
         <span class="h2">
          Neuroleptic malignant syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         The pathognomonic features of neuroleptic malignant syndrome (NMS) are fever, muscle rigidity, mental status changes, and autonomic instability, generally accompanied by rhabdomyolysis and creatine kinase elevation [
         <a href="#rid68">
          68,69
         </a>
         ]. The condition is rare but potentially fatal and constitutes a medical emergency. The physiological mechanism of NMS is unknown. (See
         <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">
          "Neuroleptic malignant syndrome"
         </a>
         .)
        </p>
        <p>
         No differences have been demonstrated in risk of NMS among the FGAs, all of which have case reports of the syndrome. The single strongest predictive factor is a prior episode of NMS. Other frequently cited factors include recently initiated treatment, aggressive dosing, parenteral administration, acute medical illness, and dehydration.
        </p>
        <p>
         The most important element of prevention is to screen patients for prior episodes of NMS. The syndrome should be suspected if more than one of the essential features is present, and further evaluation should take place in a medical emergency department.
        </p>
        <p class="headingAnchor" id="H16918940">
         <span class="h2">
          Ocular
         </span>
         <span class="headingEndMark">
          —
         </span>
         Pigmentary retinopathy (retinitis pigmentosa) and deposits in the lens or cornea leading to cataracts are the primary ocular issues reported with FGAs. Among these drugs, those chemically classified as phenothiazines (
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">
          fluphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">
          thioridazine
         </a>
         , and
         <a class="drug drug_general" data-topicid="10020" href="/z/d/drug information/10020.html" rel="external">
          trifluoperazine
         </a>
         ) are generally found to carry the highest risk. Despite the differences in risk for ocular side effects, all FGAs carry the same manufacturers’ recommendation for annual inquiry regarding visual problems and an ocular examination every two years in patients up to age 40 and annually thereafter.
        </p>
        <p>
         Ocular issues specific to individual FGAs include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">
          Thioridazine
         </a>
         has most frequently been associated with pigmentary retinopathy [
         <a href="#rid70">
          70-73
         </a>
         ]. Doses of thioridazine at or above 800 mg per day carry an especially high risk and the manufacturer accordingly recommends that doses be limited to 600 mg per day. A similar, but less frequent, pattern of risk at higher doses has been reported for
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">
          fluphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         , and
         <a class="drug drug_general" data-topicid="10020" href="/z/d/drug information/10020.html" rel="external">
          trifluoperazine
         </a>
         . Retinal problems have not been reported with
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9576" href="/z/d/drug information/9576.html" rel="external">
          loxapine
         </a>
         , or
         <a class="drug drug_general" data-topicid="9773" href="/z/d/drug information/9773.html" rel="external">
          pimozide
         </a>
         . (See
         <a class="medical medical_review" href="/z/d/html/6905.html" rel="external">
          "Retinitis pigmentosa: Clinical presentation and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Evidence of corneal and lenticular deposits potentially leading to cataracts has been found in as many as one-third of patients taking
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         or
         <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">
          thioridazine
         </a>
         at high doses over long periods [
         <a href="#rid73">
          73
         </a>
         ].
         <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">
          Fluphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         , and
         <a class="drug drug_general" data-topicid="10020" href="/z/d/drug information/10020.html" rel="external">
          trifluoperazine
         </a>
         showed lower rates of the same phenomenon. As with retinal problems,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9576" href="/z/d/drug information/9576.html" rel="external">
          loxapine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9773" href="/z/d/drug information/9773.html" rel="external">
          pimozide
         </a>
         have not been associated with these changes.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          Perphenazine
         </a>
         has been associated with rare cases of epithelial keratopathies, mydriasis, myosis, and photophobia. The only issues associated with
         <a class="drug drug_general" data-topicid="9773" href="/z/d/drug information/9773.html" rel="external">
          pimozide
         </a>
         are photophobia and accommodation problems. Although worsening of narrow-angle glaucoma is theoretically possible with any anticholinergic medication, and all FGAs include a caution when used in these patients, a 2010 review found no reports of glaucoma with any of these medications [
         <a href="#rid73">
          73
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H16918947">
         <span class="h2">
          Prolactin elevation
         </span>
         <span class="headingEndMark">
          —
         </span>
         All FGAs have been shown to elevate prolactin levels, apparently through blockade of tuberoinfundibular dopamine, allowing uninhibited secretion of pituitary prolactin. Both men and women taking FGAs typically have prolactin levels two to three times higher than normal and, although there is some evidence that patients may develop tolerance to this effect, the majority of patients continue to have elevated levels [
         <a href="#rid74">
          74
         </a>
         ]. The clinical significance of excessive prolactin includes risk of menstrual irregularities, infertility, galactorrhea, loss of libido, and erectile and ejaculatory dysfunction. Patients on any FGA should be asked about sexual dysfunction and abnormal lactation annually, and a prolactin level should be included in the evaluation of these symptoms [
         <a href="#rid47">
          47
         </a>
         ]. The relationship of elevated prolactin to the development of pituitary adenoma and the progression of breast cancer remains uncertain [
         <a href="#rid74">
          74,75
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3931910724">
         <span class="h2">
          Sexual dysfunction
         </span>
         <span class="headingEndMark">
          —
         </span>
         Even in the absence of prolactin elevation, all FGAs have been associated with impaired sexual function. A 2011 review concluded that more than 70 percent of patients on
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         experienced some form of sexual dysfunction [
         <a href="#rid76">
          76
         </a>
         ]. A 2013 meta-analysis reported these symptoms in 45 percent of haloperidol- and 60 percent of thioridazine-treated patients [
         <a href="#rid77">
          77
         </a>
         ]. In this study, the risk of any sexual dysfunction with haloperidol was only slightly greater than that reported for the SGAs
         <a class="drug drug_general" data-topicid="9868" href="/z/d/drug information/9868.html" rel="external">
          risperidone
         </a>
         and
         <a class="drug drug_general" data-topicid="9716" href="/z/d/drug information/9716.html" rel="external">
          olanzapine
         </a>
         , but the risk of arousal or orgasmic problems with
         <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">
          thioridazine
         </a>
         was twofold higher.
        </p>
        <p class="headingAnchor" id="H16919036">
         <span class="h2">
          Sedation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The lower-potency FGAs
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         and
         <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">
          thioridazine
         </a>
         have high levels of histaminic H1 receptor antagonism and are highly sedating [
         <a href="#rid17">
          17
         </a>
         ], a quality that sometimes leads to the use of chlorpromazine for sedation of severely agitated psychotic or delirious inpatients [
         <a href="#rid78">
          78
         </a>
         ]. Outpatients receiving these drugs should be cautioned about driving or operating machinery. Chlorpromazine has been used in surgical, medical, and radiologic settings for conscious sedation with efficacy comparable to that of
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         [
         <a href="#rid79">
          79
         </a>
         ]. The higher-potency drugs are significantly less sedating, especially
         <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">
          fluphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9773" href="/z/d/drug information/9773.html" rel="external">
          pimozide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9993" href="/z/d/drug information/9993.html" rel="external">
          thiothixene
         </a>
         , and
         <a class="drug drug_general" data-topicid="10020" href="/z/d/drug information/10020.html" rel="external">
          trifluoperazine
         </a>
         [
         <a href="#rid17">
          17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H1710144670">
         <span class="h2">
          Falls
         </span>
         <span class="headingEndMark">
          —
         </span>
         Antipsychotic medications may cause falls and fractures as the result of somnolence, postural hypotension, and/or motor and sensory instability [
         <a href="#rid80">
          80,81
         </a>
         ]. For patients with conditions or taking medications that could exacerbate these effects, the FDA recommended that a fall risk assessment be completed when initiating antipsychotic treatment and recurrently for patients continuing on long-term antipsychotics.
        </p>
        <p class="headingAnchor" id="H16919131">
         <span class="h2">
          Seizure
         </span>
         <span class="headingEndMark">
          —
         </span>
         A 2015 nested case-control analysis of over 60,000 patients from the United Kingdom found that the risk of seizure with FGAs was 49.4 per 10,000 person-years of exposure to
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         and
         <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">
          thioridazine
         </a>
         , and 59.1 for
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         and
         <a class="drug drug_general" data-topicid="10020" href="/z/d/drug information/10020.html" rel="external">
          trifluoperazine
         </a>
         , compared with 11.7 for control patients [
         <a href="#rid82">
          82
         </a>
         ]. The increased seizure risk with FGAs is generally attributed to a lowering of seizure threshold rather than to new-onset problems. Manufacturer guidance for each FGA cautions about use in patients at risk for seizures, including those taking other medications that lower seizure threshold.
        </p>
        <p class="headingAnchor" id="H680779980">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/117525.html" rel="external">
          "Society guideline links: Psychotic disorders"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H272233927">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Pharmacology
         </strong>
         – The mechanism of action of first-generation antipsychotics (FGAs) appears to be postsynaptic blockade of brain dopamine D2 receptors. Aside from their common activity as D2 antagonists, each FGA has distinct effects on neuronal 5-HT2a, alpha-1, histaminic, and muscarinic receptors, which generally correspond to their individual side effect profiles, as shown in the table  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Pharmacology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Potency
         </strong>
         – Pharmacological differences are the basis for classification of FGAs by potency. High-potency agents (eg,
         <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">
          fluphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9760" href="/z/d/drug information/9760.html" rel="external">
          perphenazine
         </a>
         ) have less sedation, less anticholinergic activity, and less weight gain but a higher risk for extrapyramidal symptoms (EPS) than low-potency agents (eg,
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          chlorpromazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">
          thioridazine
         </a>
         )  (
         <a class="graphic graphic_table graphicRef60624" href="/z/d/graphic/60624.html" rel="external">
          table 2
         </a>
         ). (See
         <a class="local">
          'High- and low-potency FGAs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Metabolism and drug interactions
         </strong>
         – All FGAs undergo metabolism via the cytochrome P450 system. This makes the drugs susceptible to liver impairment and drug-drug interactions. The FGAs can interact with drugs that have potent effects on CYP metabolism, including the antidepressants
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9743" href="/z/d/drug information/9743.html" rel="external">
          paroxetine
         </a>
         , and
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         , and the mood stabilizer
         <a class="drug drug_general" data-topicid="9198" href="/z/d/drug information/9198.html" rel="external">
          carbamazepine
         </a>
         . (See
         <a class="local">
          'Metabolic activation and clearance'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Preference for second-generation antipsychotics (SGAs)
         </strong>
         – Due to the propensity of FGAs to cause EPS and tardive dyskinesia, SGAs are typically the preferred choice over FGAs in the treatment of psychosis. (See
         <a class="local">
          'Administration'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Side effects
         </strong>
         – While antipsychotic medications are believed to be comparable in effectiveness (with the exception of
         <a class="drug drug_general" data-topicid="9289" href="/z/d/drug information/9289.html" rel="external">
          clozapine
         </a>
         for treatment-resistant schizophrenia), they differ in side effect profiles both individually and between FGAs and SGAs. Our choice of antipsychotic is influenced by its side effect profile, and the patient’s clinical status and risk factors. (See
         <a class="local">
          'Side effects'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Extrapyramidal symptoms
         </strong>
         – These include rigidity, bradykinesia, tremor, and akathisia (restlessness). Among the FGAs, the high-potency drugs (eg,
         <a class="drug drug_general" data-topicid="8467" href="/z/d/drug information/8467.html" rel="external">
          fluphenazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         ,
         <a class="drug drug_general" data-topicid="9773" href="/z/d/drug information/9773.html" rel="external">
          pimozide
         </a>
         , and
         <a class="drug drug_general" data-topicid="9993" href="/z/d/drug information/9993.html" rel="external">
          thiothixene
         </a>
         are usually associated with the highest risk of EPS)  (
         <a class="graphic graphic_table graphicRef82533" href="/z/d/graphic/82533.html" rel="external">
          table 1
         </a>
         ). (See
         <a class="local">
          'Extrapyramidal symptoms'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Tardive dyskinesia (TD)
         </strong>
         – TD is characterized by involuntary choreoathetoid movements of the mouth, tongue, face, extremities, or trunk. TD risk increases with age, time of exposure to the medications, and prior development of EPS. TD has been reported with all FGAs at a cumulative rate of 5 percent per year, with higher risk in the older population. (See
         <a class="local">
          'Tardive dyskinesia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Metabolic syndrome
         </strong>
         – Weight gain, diabetes, dyslipidemia, diabetic ketoacidosis, and cardiovascular disease constitute a metabolic syndrome associated with antipsychotic medications (FGAs, SGAs). The potential morbidity of these symptoms has led to routine monitoring of weight, waist circumference, blood pressure, fasting glucose, and lipid profile of patients taking any of the antipsychotic medications  (
         <a class="graphic graphic_table graphicRef74435" href="/z/d/graphic/74435.html" rel="external">
          table 6
         </a>
         ). (See
         <a class="local">
          'Metabolic syndrome'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          QT prolongation and sudden death
         </strong>
         – Sudden death, believed in most cases to be caused by QT prolongation, has been reported with exposure to any antipsychotic medication.
         <a class="drug drug_general" data-topicid="9252" href="/z/d/drug information/9252.html" rel="external">
          Chlorpromazine
         </a>
         ,
         <a class="drug drug_general" data-topicid="9991" href="/z/d/drug information/9991.html" rel="external">
          thioridazine
         </a>
         , and intravenous
         <a class="drug drug_general" data-topicid="8516" href="/z/d/drug information/8516.html" rel="external">
          haloperidol
         </a>
         are known to be the highest risk. We obtain an electrocardiogram and serum potassium level prior to the first dose of these agents.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Increased risk of mortality
         </strong>
         – Accumulating data from both observational studies and pooled analyses of trials indicate that antipsychotic medications are associated with a 1.6- to 1.7-fold increased risk of stroke, myocardial infarction, and death when used to treat behavioral symptoms in older adults with dementia.
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Neuroleptic malignant syndrome (NMS)
         </strong>
         – NMS is a syndrome of fever, muscle rigidity, mental status changes, and autonomic instability, generally accompanied by rhabdomyolysis and creatine kinase elevation. The condition is rare but potentially fatal and constitutes a medical emergency. The physiological mechanism of NMS is unknown. (See
         <a class="medical medical_review" href="/z/d/html/4829.html" rel="external">
          "Neuroleptic malignant syndrome"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         <strong>
          Others
         </strong>
         –
         <strong>
         </strong>
         Orthostatic hypotension, dry mouth, constipation, pigmentary retinopathy, sexual dysfunction, falls, seizures are seen less often, and rare cases of agranulocytosis have been reported.
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Stone JM, Davis JM, Leucht S, Pilowsky LS. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull 2009; 35:789.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000; 157:514.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Odou P, Vaiva G, Luyckx M, et al. Neuroleptic monitoring: relation between antipsychotic efficiency and radioreceptor assay of serum haloperidol. Eur J Clin Pharmacol 1996; 50:357.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ulrich S, Neuhof S, Braun V, Meyer FP. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. Pharmacopsychiatry 1998; 31:163.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spyker DA, Munzar P, Cassella JV. Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers. J Clin Pharmacol 2010; 50:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lesem MD, Tran-Johnson TK, Riesenberg RA, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry 2011; 198:51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kwentus J, Riesenberg RA, Marandi M, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord 2012; 14:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dahl ML. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 2002; 41:453.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 2009; 48:761.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Midha KK, Hubbard JW, McKay G, et al. The role of metabolites in a bioequivalence study 1: loxapine, 7-hydroxyloxapine and 8-hydroxyloxapine. Int J Clin Pharmacol Ther Toxicol 1993; 31:177.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Saddichha S, Manjunatha N, Ameen S, Akhtar S. Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study. Schizophr Res 2008; 101:266.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Stimmel GL, Falloon IR. Chlorpromazine plasma levels, adverse effects, and tobacco smoking: case report. J Clin Psychiatry 1983; 44:420.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pantuck EJ, Pantuck CB, Anderson KE, et al. Cigarette smoking and chlorpromazine disposition and actions. Clin Pharmacol Ther 1982; 31:533.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ereshefsky L, Saklad SR, Watanabe MD, et al. Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. J Clin Psychopharmacol 1991; 11:296.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008; 28:203.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013; 382:951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Coley KC, Carter CS, DaPos SV, et al. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. J Clin Psychiatry 1999; 60:850.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993; 50:723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993; 54:133.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006; 21:589.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Correll CU, Leucht S, Kane JM. Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies. Am J Psychiatry 2004; 161:414.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sabé M, Pallis K, Solmi M, et al. Comparative Effects of 11 Antipsychotics on Weight Gain and Metabolic Function in Patients With Acute Schizophrenia: A Dose-Response Meta-Analysis. J Clin Psychiatry 2023; 84.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Roerig JL, Steffen KJ, Mitchell JE. Atypical antipsychotic-induced weight gain: insights into mechanisms of action. CNS Drugs 2011; 25:1035.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ferentinos P, Dikeos D. Genetic correlates of medical comorbidity associated with schizophrenia and treatment with antipsychotics. Curr Opin Psychiatry 2012; 25:381.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kane JM, Davis JM, Schooler N, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 2002; 159:554.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serafetinides EA, Collins S, Clark ML. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. J Nerv Ment Dis 1972; 154:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dossenbach M, Treuer T, Kryzhanovskaya L, et al. Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa. J Clin Psychopharmacol 2007; 27:329.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70:1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Vidarsdottir S, de Leeuw van Weenen JE, Frölich M, et al. Effects of olanzapine and haloperidol on the metabolic status of healthy men. J Clin Endocrinol Metab 2010; 95:118.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cookson JC. Side effects during long-term treatment with depot antipsychotic medication. Clin Neuropharmacol 1991; 14 Suppl 2:S24.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brambilla F, Guastalla A, Guerrini A, et al. Glucose-insulin metabolism in chronic schizophrenia. Dis Nerv Syst 1976; 37:98.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Doss FW. The effect of antipsychotic drugs on body weight: a retrospective review. J Clin Psychiatry 1979; 40:528.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, North American Association for the Study of Obesity. Consensus development conference on antipsychotic drugs and obesity and diabetes. Diabetes Care 2004; 27:596.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen J, Graff C, Kanters JK, et al. Assessing QT interval prolongation and its associated risks with antipsychotics. CNS Drugs 2011; 25:473.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fenton M, Rathbone J, Reilly J, Sultana A. Thioridazine for schizophrenia. Cochrane Database Syst Rev 2007; :CD001944.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004; 24:62.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reilly JG, Ayis SA, Ferrier IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355:1048.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salvo F, Pariente A, Shakir S, et al. Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies. Clin Pharmacol Ther 2016; 99:306.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Salih IS, Thanacoody RH, McKay GA, Thomas SH. Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. Clin Pharmacol Ther 2007; 82:548.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shah AA, Aftab A, Coverdale J. QTc prolongation with antipsychotics: is routine ECG monitoring recommended? J Psychiatr Pract 2014; 20:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moss AJ. Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol 1993; 72:23B.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sharma ND, Rosman HS, Padhi ID, Tisdale JE. Torsades de Pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lawrence KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 1997; 17:531.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Riker RR, Fraser GL, Cox PM. Continuous infusion of haloperidol controls agitation in critically ill patients. Crit Care Med 1994; 22:433.
          </a>
         </li>
         <li class="breakAll">
          U.S. Food and Drug Administration.  Information for Healthcare Professionals: Haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate). FDA Alert. [9/2007]. Available at: http://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085203.htm.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1989; 46:722.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 1999; 65:10.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fruensgaard K. Parenteral treatment of acute psychotic patients with agitation: a review. Curr Med Res Opin 1978; 5:593.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cassella JV, Spyker DA, Yeung PP. A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers. Int J Clin Pharmacol Ther 2015; 53:963.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DiGiacomo J. Cardiovascular effects of psychotropic drugs. Cardiovasc Rev Rep 1989; 10:31.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tuason VB, Escobar JI, Garvey M, Schiele B. Loxapine versus chlorpromazine in paranoid schizophrenia: a double-blind study. J Clin Psychiatry 1984; 45:158.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Atypical antipsychotics in the elderly. Med Lett Drugs Ther 2005; 47:61.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneider LS, Dagerman KS, Insel P. Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials. JAMA 2005; 294:1934.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ballard C, Hanney ML, Theodoulou M, et al. The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial. Lancet Neurol 2009; 8:151.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang PS, Schneeweiss S, Avorn J, et al. Risk of death in elderly users of conventional vs. atypical antipsychotic medications. N Engl J Med 2005; 353:2335.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schneeweiss S, Setoguchi S, Brookhart A, et al. Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients. CMAJ 2007; 176:627.
          </a>
         </li>
         <li class="breakAll">
          US Food and Drug Administration. Public Health Advisory: Deaths with Antipsychotics in Elderly Patients with Behavioral Disturbances. Available at http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformationforpatientsandproviders/ucm053171 (Accessed on November 11, 2015).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gill SS, Bronskill SE, Normand SL, et al. Antipsychotic drug use and mortality in older adults with dementia. Ann Intern Med 2007; 146:775.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Murray-Thomas T, Jones ME, Patel D, et al. Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database. Cardiovasc Psychiatry Neurol 2013; 2013:247486.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Huybrechts KF, Gerhard T, Crystal S, et al. Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study. BMJ 2012; 344:e977.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Park Y, Bateman BT, Kim DH, et al. Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study. BMJ 2018; 360:k1218.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Koponen M, Taipale H, Lavikainen P, et al. Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer's Disease. J Alzheimers Dis 2017; 56:107.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Flanagan RJ, Dunk L. Haematological toxicity of drugs used in psychiatry. Hum Psychopharmacol 2008; 23 Suppl 1:27.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Regal RE, Billi JE, Glazer HM. Phenothiazine-induced cholestatic jaundice. Clin Pharm 1987; 6:787.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Watson RG, Olomu A, Clements D, et al. A proposed mechanism for chlorpromazine jaundice--defective hepatic sulphoxidation combined with rapid hydroxylation. J Hepatol 1988; 7:72.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Velamoor VR. Neuroleptic malignant syndrome. Recognition, prevention and management. Drug Saf 1998; 19:73.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Caroff SN, Mann SC. Neuroleptic malignant syndrome. Med Clin North Am 1993; 77:185.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hagopian V, Stratton DB, Busiek RD. Five cases of pigmentary retinopathy associated with thioridazine administration. Am J Psychiatry 1966; 123:97.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tekell JL, Silva JA, Maas JA, et al. Thioridazine-induced retinopathy. Am J Psychiatry 1996; 153:1234.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rennie IG. Clinically important ocular reactions to systemic drug therapy. Drug Saf 1993; 9:196.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richa S, Yazbek JC. Ocular adverse effects of common psychotropic agents: a review. CNS Drugs 2010; 24:501.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peuskens J, Pani L, Detraux J, De Hert M. The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. CNS Drugs 2014; 28:421.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Froes Brandao D, Strasser-Weippl K, Goss PE. Prolactin and breast cancer: The need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: A review. Cancer 2016; 122:184.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Serretti A, Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int Clin Psychopharmacol 2011; 26:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           La Torre A, Conca A, Duffy D, et al. Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics. Pharmacopsychiatry 2013; 46:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dean AJ, McDermott BM, Marshall RT. PRN sedation-patterns of prescribing and administration in a child and adolescent mental health inpatient service. Eur Child Adolesc Psychiatry 2006; 15:277.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Green JF, McElholm A, King DJ. A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam. Psychopharmacology (Berl) 1996; 128:67.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Landi F, Onder G, Cesari M, et al. Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study. J Gerontol A Biol Sci Med Sci 2005; 60:622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ramcharran D, Qiu H, Schuemie MJ, Ryan PB. Atypical Antipsychotics and the Risk of Falls and Fractures Among Older Adults: An Emulation Analysis and an Evaluation of Additional Confounding Control Strategies. J Clin Psychopharmacol 2017; 37:162.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bloechliger M, Rüegg S, Jick SS, et al. Antipsychotic drug use and the risk of seizures: follow-up study with a nested case-control analysis. CNS Drugs 2015; 29:591.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 14773 Version 32.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18303092" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11873706" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Atypical antipsychotics: mechanism of action.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10739409" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8839656" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Neuroleptic monitoring: relation between antipsychotic efficiency and radioreceptor assay of serum haloperidol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9832347" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19915181" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Pharmacokinetics of loxapine following inhalation of a thermally generated aerosol in healthy volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21200077" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22329470" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12083975" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19902987" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8500919" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : The role of metabolites in a bioequivalence study 1: loxapine, 7-hydroxyloxapine and 8-hydroxyloxapine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18262771" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6643405" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Chlorpromazine plasma levels, adverse effects, and tobacco smoking: case report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7060333" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Cigarette smoking and chlorpromazine disposition and actions.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1765572" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Thiothixene pharmacokinetic interactions: a study of hepatic enzyme inducers, clearance inhibitors, and demographic variables.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18344731" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23810019" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10665632" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8102845" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8098030" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16532448" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14992963" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Lower risk for tardive dyskinesia associated with second-generation antipsychotics: a systematic review of 1-year studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36752753" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Comparative Effects of 11 Antipsychotics on Weight Gain and Metabolic Function in Patients With Acute Schizophrenia: A Dose-Response Meta-Analysis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22133326" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Atypical antipsychotic-induced weight gain: insights into mechanisms of action.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22842659" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Genetic correlates of medical comorbidity associated with schizophrenia and treatment with antipsychotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11925292" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4550211" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17632215" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15246458" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The effects of antipsychotic therapy on serum lipids: a comprehensive review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19906788" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Effects of olanzapine and haloperidol on the metabolic status of healthy men.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1751940" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Side effects during long-term treatment with depot antipsychotic medication.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1245144" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Glucose-insulin metabolism in chronic schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/40965" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : The effect of antipsychotic drugs on body weight: a retrospective review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14747245" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Consensus development conference on antipsychotic drugs and obesity and diabetes.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21649448" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Assessing QT interval prolongation and its associated risks with antipsychotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17636691" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Thioridazine for schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14709949" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10744090" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26272741" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Sudden cardiac and sudden unexpected death related to antipsychotics: A meta-analysis of observational studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17410120" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24847993" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : QTc prolongation with antipsychotics: is routine ECG monitoring recommended?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8256751" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Measurement of the QT interval and the risk associated with QTc interval prolongation: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9591913" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Torsades de Pointes associated with intravenous haloperidol in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9165555" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8124994" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Continuous infusion of haloperidol controls agitation in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8124994" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Continuous infusion of haloperidol controls agitation in critically ill patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15285957" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Physical health monitoring of patients with schizophrenia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2665687" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9951426" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30596" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Parenteral treatment of acute psychotic patients with agitation: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26501204" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : A randomized, placebo-controlled repeat-dose thorough QT study of inhaled loxapine in healthy volunteers.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Cardiovascular effects of psychotropic drugs
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/6370967" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Loxapine versus chlorpromazine in paranoid schizophrenia: a double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16052161" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Atypical antipsychotics in the elderly.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16234500" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19138567" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16319382" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Risk of death in elderly users of conventional vs. atypical antipsychotic medications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17325327" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17325327" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Risk of death associated with the use of conventional versus atypical antipsychotic drugs among elderly patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17548409" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Antipsychotic drug use and mortality in older adults with dementia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24455199" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Risk of mortality (including sudden cardiac death) and major cardiovascular events in atypical and typical antipsychotic users: a study with the general practice research database.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22362541" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Differential risk of death in older residents in nursing homes prescribed specific antipsychotic drugs: population based cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29592958" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Use of haloperidol versus atypical antipsychotics and risk of in-hospital death in patients with acute myocardial infarction: cohort study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27935554" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Risk of Mortality Associated with Antipsychotic Monotherapy and Polypharmacy Among Community-Dwelling Persons with Alzheimer's Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18098216" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Haematological toxicity of drugs used in psychiatry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2905941" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Phenothiazine-induced cholestatic jaundice.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3183354" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : A proposed mechanism for chlorpromazine jaundice--defective hepatic sulphoxidation combined with rapid hydroxylation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9673859" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Neuroleptic malignant syndrome. Recognition, prevention and management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8093494" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Neuroleptic malignant syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5935198" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Five cases of pigmentary retinopathy associated with thioridazine administration.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8780438" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Thioridazine-induced retinopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8240725" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Clinically important ocular reactions to systemic drug therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20443647" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Ocular adverse effects of common psychotropic agents: a review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/24677189" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26457577" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Prolactin and breast cancer: The need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: A review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21191308" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23737244" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Sexual dysfunction related to psychotropic drugs: a critical review part II: antipsychotics.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16583125" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : PRN sedation-patterns of prescribing and administration in a child and adolescent mental health inpatient service.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8944408" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : A comparison of the sedative and amnestic effects of chlorpromazine and lorazepam.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15972615" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Psychotropic medications and risk for falls among community-dwelling frail older people: an observational study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28225746" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Atypical Antipsychotics and the Risk of Falls and Fractures Among Older Adults: An Emulation Analysis and an Evaluation of Additional Confounding Control Strategies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26242478" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : Antipsychotic drug use and the risk of seizures: follow-up study with a nested case-control analysis.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
